Market Place
Sourcing Support
Harmony Biosciences Prices Public Offering of Common Stock
30 Oct 2024 //
PR NEWSWIRE
Harmony Biosciences Reports Strong Q3 2024 Financial Results
29 Oct 2024 //
PR NEWSWIRE
Harmony Biosciences Announces Commencement Of Public Offering
29 Oct 2024 //
PR NEWSWIRE
Harmony Biosciences Highlights Late-Stage Pipeline at Investor Day
01 Oct 2024 //
PR NEWSWIRE
Harmony Biosciences Reports Strong Q2 2024 Results
06 Aug 2024 //
GLOBENEWSWIRE
HARMONY BIOSCIENCES Acknowledges FDA Action on WAKIX® Citizen Petition
25 Jun 2024 //
PR NEWSWIRE
Harmony Receives FDA Approval For WAKIX® (Pitolisant) In Pediatric Narcolepsy
24 Jun 2024 //
PR NEWSWIRE
Harmony Bio Q1 Results, Pitolisant Franchise Expansion
30 Apr 2024 //
GLOBENEWSWIRE
Harmony Biosciences Buys Epygenix Therapeutics For Initial $35 Million
30 Apr 2024 //
PR NEWSWIRE
Harmony To Develop, Commercialize Orexin-2 Agonist TPM-1116
11 Apr 2024 //
PR NEWSWIRE
Harmony Bio Initiates Ph 3 of Pitolisant in Patients with Prader-Willi Syndrome
03 Apr 2024 //
PR NEWSWIRE
Harmony Biosciences to participate in 23rd Annual Needham Virtual Healthcare Conference
26 Mar 2024 //
PRESS RELEASE
Harmony Biosciences Certified as a Great Place to Work
06 Mar 2024 //
PRESS RELEASE
Harmony Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results
22 Feb 2024 //
GLOBENEWSWIRE
Harmony Biosciences Receives FDA Orphan Drug Designation For Pitolisant
20 Feb 2024 //
PR NEWSWIRE
Harmony Announces Positive Data From Phase 2 Study Evaluating Pitolisant
07 Dec 2023 //
PR NEWSWIRE
Harmony Bio Ranked Among Top 25 Fastest-Growing Companies In North America
15 Nov 2023 //
PR NEWSWIRE
Harmony Biosciences Reports Strong Third Quarter 2023 Financial Results
31 Oct 2023 //
GLOBENEWSWIRE
Harmony Bio Announces Topline Data From Phase 3 Study Evaluating Pitolisant
13 Oct 2023 //
PR NEWSWIRE
Harmony Biosciences Completes Acquisition of Zynerba Pharmaceuticals And Expands Pipeline
11 Oct 2023 //
PR NEWSWIRE
Harmony Biosciences Presents Data From Phase 2 Signal Detection Study
05 Oct 2023 //
PR NEWSWIRE
Important Information for Zynerba Stockholders to Tender Shares
04 Oct 2023 //
GLOBENEWSWIRE
Harmony Announces Extension Of Tender Offer To Acquire Zynerba Pharma
27 Sep 2023 //
PR NEWSWIRE
Harmony Jeffrey M. Dayno Named To Pharmavoice 100 List Of Top Industry Leaders
20 Sep 2023 //
PR NEWSWIRE
HARMONY BIOSCIENCES TO PARTICIPATE IN 2023 CANTOR GLOBAL HEALTHCARE CONFERENCE
13 Sep 2023 //
PR NEWSWIRE
Harmony Biosciences Announces FDA Orphan Drug Designation For Pitolisant
07 Sep 2023 //
PR NEWSWIRE
HARMONY BIOSCIENCES REITERATES CONFIDENCE IN WAKIX® (PITOLISANT) PATENTS
28 Aug 2023 //
PR NEWSWIRE
Harmony buys cannabidiol firm Zynerba in $200m deal
16 Aug 2023 //
PHARMAPHORUM
Harmony Biosciences To Acquire Zynerba Pharma For Up To $200 Mln
15 Aug 2023 //
NASDAQ
HARMONY BIOSCIENCES ANNOUNCES $125 MILLION SHARE REPURCHASE PROGRAM
01 Aug 2023 //
PR NEWSWIRE
Harmony Bio Reports Second Quarter 2023 Financial Results and Business Updates
01 Aug 2023 //
GLOBENEWSWIRE
Harmony Bio Announces Plans To Initiate Piii Registrational Study Of Pitolisant
20 Jul 2023 //
PR NEWSWIRE
Harmony Announces Positive Phase 2 Signal Detection Study Evaluating Pitolisant
06 Jun 2023 //
PR NEWSWIRE
HARMONY COMPLETES ENROLLMENT OF PHASE 3 REGISTRATIONAL INTUNE STUDY
25 May 2023 //
PR NEWSWIRE
HARMONY BIOSCIENCES TO PRESENT NEW WAKIX® (PITOLISANT) SAFETY
10 May 2023 //
PR NEWSWIRE
Harmony Biosciences Reports First Quarter 2023 FYR and Business Updates
02 May 2023 //
GLOBENEWSWIRE
Harmony Announces Accelerated Timeline For Phase 3 Intune Study
29 Mar 2023 //
PR NEWSWIRE
Scorpion Capital unleashes venom in Harmony Bio short report
28 Mar 2023 //
FIERCE PHARMA
Harmony Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results
21 Feb 2023 //
GLOBENEWSWIRE
Harmony Biosciences To Participate In Piper Sandler 34Th Healthcare Conference
09 Nov 2022 //
PRNEWSWIRE
Harmony Biosciences Reports 3Q 2022 FYR and Business Updates
01 Nov 2022 //
GLOBENEWSWIRE
Harmony Biosciences (HRMY) Stock: Why It Increased 7.22% Today
14 Oct 2022 //
PULSE
Harmony Biosciences To Participate In Upcoming Investor Conferences
17 Aug 2022 //
PRNEWSWIRE
Harmony Biosciences Reports Second Quarter 2022 Financial
02 Aug 2022 //
PRESS RELEASE
Harmony Biosciences Presents Post-Hoc Analysis Of Wakix Pivotal Data
06 Jun 2022 //
PRNEWSWIRE
Harmony Biosciences Reports First Quarter 2022 Financial Results
03 May 2022 //
GLOBENEWSWIRE
Harmony begins Phase III idiopathic hypersomnia treatment trial
28 Apr 2022 //
CLINICALTRIALSARENA
Harmony Biosciences Initiates Piii Trial of Pitolisant in Idiopathic Hypersomnia
27 Apr 2022 //
PRNEWSWIRE
Harmony Biosciences Announces Date Of First Quarter 2022 Financial Results
19 Apr 2022 //
PRNEWSWIRE
Harmony Bio says Applications Open March 18 For 2022 Patients At Heart Program
17 Mar 2022 //
PRNEWSWIRE
Harmony Biosciences To Participate In Two Investor Conferences In March
09 Mar 2022 //
PRNEWSWIRE
Harmony Initiates Phase 3 Trial For Idiopathic Hypersomnia
01 Dec 2021 //
PRNEWSWIRE
Harmony Biosciences Appoints Linda Szyper To Its Board Of Directors
22 Nov 2021 //
PRNEWSWIRE
Harmony Biosciences to be Added to the S&P SmallCap 600 Index
21 Oct 2021 //
BIOSPACE
Harmony Biosciences Announces Winners of Patients at the Heart and Progress
22 Sep 2021 //
PRNEWSWIRE
Harmony Biosciences Announces Inclusion Of WAKIX® (pitolisant)
02 Sep 2021 //
PRNEWSWIRE
Harmony Biosciences To Participate In Three Investor Conferences In September
02 Sep 2021 //
PRNEWSWIRE
Harmony Biosciences To Present New Data Analyses For WAKIX At The SLEEP 2021
07 Jun 2021 //
PRNEWSWIRE
Harmony Biosciences to Present at the Oppenheimer Rare and Orphan Disease Summit
18 May 2021 //
PRNEWSWIRE
